We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Upgraded Optical Component Enhances Automated Living Cell Research System

By LabMedica International staff writers
Posted on 21 Dec 2010
An upgraded automatic imaging system equipped with state-of-the-art optics is now available for studying living cells under flow conditions.

The Fluxion Biosciences Inc. More...
(San Francisco, CA, USA) BioFlux 1000 system has enabled a wide variety of cell-based assays in the fields of immunology, vascular biology, microbiology, cancer research, stem cells, and more. Many of these applications, such as platelet adhesion, cell adhesion, rolling velocity, transmigration, and stem cell differentiation, have benefited from the system's ability to create a physiologically relevant shear-flow profile. Other applications, such as wound healing, chemotaxis, pharmacology, and neurite-outgrowth assays, benefited from its ability to introduce compounds and gradients in a time-resolved and well-controlled manner.

The BioFlux system utilizes a unique microfluidic design to enable automated cellular analyses in the presence of controlled shear flow. Micron-scale flow channel devices are integrated into standard microtiter plates. The lower surface of these devices is formed by cover slip glass optimized for high resolution microscopy data.

The new BioFlux 1000Z instrument maintains the BioFlux 1000's integrated system for automated, high-throughput shear-flow assays. This includes the BioFlux controller and a integrated imaging workstation, including a state of the art inverted microscope, automated XY stage, automated fluorescence, auto focus module, CCD camera, and PC workstation. In the new BioFlux 1000Z system, the optical component is based on the Zeiss (Jena, Germany) AxioObserver microscope. New modules for this platform include Zeiss' proprietary Definite Focus LED-based autofocus mechanism and PlasDIC module for differential internal contrast imaging.

"We are pleased to launch this new addition to the BioFlux product family,” said Michael Schwartz, program director at Fluxion Biosciences. "Carl Zeiss has a worldwide reputation for advanced optics and superb engineering. The combination of Zeiss microscopy hardware with Fluxion's Well Plate Microfluidic technology provides an advanced solution for cellular research and drug discovery.”

Related Links:
Fluxion Biosciences Inc.
Zeiss


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.